Everything below concerns Pro-Gly-Pro. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
| Property | Value | Notes |
|---|---|---|
| Typical purity report | 95% or higher by HPLC | Area percentage at 214 nm |
| Identity confirmation | Mass spectrometry | Electrospray or MALDI |
| Powder storage | -20 C, desiccated | Protect from light |
| Solution storage | 2-8 C short term | Freeze aliquots for longer |
| Quality document | Certificate of analysis | States method and value |
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
== Species distribution and evolution == In addition to mammals, NF-κB is found in a number of simple animals as well. These include cnidarians (such as sea anemones, coral and hydra), porifera (sponges), single-celled eukaryotes including Capsaspora owczarzaki and choanoflagellates, and insects (such as moths, mosquitoes and fruitflies). The sequencing of the genomes of the mosquitoes A. aegypti and A. gambiae, and the fruitfly D. melanogaster has allowed comparative genetic and evolutionary studies on NF-κB. In those insect species, activation of NF-κB is triggered by the Toll pathway (which evolved independently in insects and mammals) and by the Imd (immune deficiency) pathway.
In 2015, AquAdvantage salmon became the first genetically modified animal to be approved for food use. Approval is for fish raised in Panama and sold in the US. The salmon were transformed with a growth hormone-regulating gene from a Pacific Chinook salmon and a promoter from an ocean pout enabling it to grow year-round instead of only during spring and summer.
Serotonin 5-HT2A receptor antagonists can block the hallucinogenic effects of serotonergic psychedelics like psilocybin in humans. Numerous drugs act as serotonin 5-HT2A receptor antagonists, including antidepressants like trazodone and mirtazapine, antipsychotics like quetiapine, olanzapine, and risperidone, and other agents like ketanserin, pimavanserin, cyproheptadine, and pizotifen. Such drugs are sometimes called "trip killers" because they can prevent or abort psychedelics' hallucinogenic effects. Serotonin 5-HT2A receptor antagonists that have been specifically shown in clinical studies to diminish or abolish psilocybin's effects include ketanserin, risperidone, and chlorpromazine. Serotonin 5-HT2A receptor antagonists like antipsychotics should be stopped five half-lives or at least seven days before a psychedelic session. The serotonin 5-HT1A receptor partial agonist buspirone has been found to markedly reduce psilocybin's hallucinogenic effects in humans. Conversely, the serotonin 5-HT1A receptor antagonist pindolol has been found to robustly potentiate the hallucinogenic effects of the related psychedelic dimethyltryptamine (DMT) in humans. Selective serotonin reuptake inhibitors (SSRIs) may modify psilocybin's effects, for instance moderately diminishing them. One clinical trial found that psilocybin's hallucinogenic and "good drug" effects were not modified by the SSRI escitalopram, but that its "bad drug effects" such as anxiety, as well as ego dissolution, were reduced, among other changes.
coli, 80% of mutations were negative, but 20% were positive, even though many had a very small effect on growth (depending on condition). Gene deletions involve removal of whole genes, so that point mutations almost always have a much smaller effect. In a similar screen in Streptococcus pneumoniae, but this time with transposon insertions, 76% of insertion mutants were classified as neutral, 16% had a significantly reduced fitness, but 6% were advantageous. This classification is obviously relative and somewhat artificial: a harmful mutation can quickly turn into a beneficial mutations when conditions change. Also, there is a gradient from harmful/beneficial to neutral, as many mutations may have small and mostly neglectable effects but under certain conditions will become relevant. Also, many traits are determined by hundreds of genes (or loci), so that each locus has only a minor effect. For instance, human height is determined by hundreds of genetic variants ("mutations") but each of them has a very minor effect on height, apart from the impact of nutrition. Height (or size) itself may be more or less beneficial as the huge range of sizes in animal or plant groups shows.
===== MeSH D08.811.277.450 – glycoside hydrolases ===== MeSH D08.811.277.450.066 – amylases MeSH D08.811.277.450.066.050 – alpha-amylase MeSH D08.811.277.450.066.100 – beta-amylase MeSH D08.811.277.450.114 – beta-fructofuranosidase MeSH D08.811.277.450.207 – chitinase MeSH D08.811.277.450.283 – dextranase MeSH D08.811.277.450.329 – disaccharidases MeSH D08.811.277.450.329.738 – sucrase MeSH D08.811.277.450.329.738.700 – sucrase-isomaltase complex MeSH D08.811.277.450.329.865 – trehalase MeSH D08.811.277.450.400 – alpha-L-fucosidase MeSH D08.811.277.450.410 – galactosidases MeSH D08.811.277.450.410.050 – alpha-galactosidase MeSH D08.811.277.450.410.100 – beta-galactosidase MeSH D08.811.277.450.410.100.500 – lactase MeSH D08.811.277.450.410.150 – ceramide trihexosidase MeSH D08.811.277.450.410.400 – galactosylceramidase MeSH D08.811.277.450.420 – glucosidases MeSH D08.811.277.450.420.050 – alpha-glucosidases MeSH D08.811.277.450.420.200 – cellulases MeSH D08.811.277.450.420.200.100 – beta-glucosidase MeSH D08.811.277.450.420.200.200 – cellulase MeSH D08.811.277.450.420.200.400 – cellulose 1,4-beta-cellobiosidase MeSH D08.811.277.450.420.200.450 – endo-1,3(4)-beta-glucanase MeSH D08.811.277.450.420.200.500 – glucan 1,3-beta-glucosidase MeSH D08.811.277.450.420.200.550 – glucan 1,4-beta-glucosidase MeSH D08.811.277.450.420.200.600 – glucan endo-1,3-beta-d-glucosidase MeSH D08.811.277.450.420.375 – glucan 1,4-alpha-glucosidase MeSH D08.811.277.450.420.450 – glycogen debranching enzyme system MeSH D08.811.277.450.420.475 – glycosylceramidase MeSH D08.811.277.450.420.475.400 – glucosylceramidase MeSH D08.811.277.450.426 – glucuronidase MeSH D08.811.277.450.483 – hexosaminidases MeSH D08.811.277.450.483.021 – acetylglucosaminidase MeSH D08.811.277.450.483.044 – alpha-N-acetylgalactosaminidase MeSH D08.811.277.450.483.112 – Beta-N-acetylgalactosaminidase MeSH D08.811.277.450.483.180 – Beta-N-acetylhexosaminidase MeSH D08.811.277.450.483.765 – Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase MeSH D08.811.277.450.529 – hyaluronoglucosaminidase MeSH D08.811.277.450.560 – iduronidase MeSH D08.811.277.450.585 – isoamylase MeSH D08.811.277.450.625 – mannosidases MeSH D08.811.277.450.625.500 – alpha-mannosidase MeSH D08.811.277.450.625.750 – beta-mannosidase MeSH D08.811.277.450.642 – muramidase MeSH D08.811.277.450.692 – neuraminidase MeSH D08.811.277.450.737 – n-glycosyl hydrolases MeSH D08.811.277.450.737.099 – dna glycosylases MeSH D08.811.277.450.737.099.500 – DNA-formamidopyrimidine glycosylase MeSH D08.811.277.450.737.099.750 – thymine dna glycosylase MeSH D08.811.277.450.737.400 – nad+ nucleosidase MeSH D08.811.277.450.737.400.060 – adp-ribosyl cyclase MeSH D08.811.277.450.737.400.060.500 – antigens, cd38 MeSH D08.811.277.450.770 – oligo-1,6-glucosidase MeSH D08.811.277.450.770.800 – sucrase-isomaltase complex MeSH D08.811.277.450.800 – polygalacturonase MeSH D08.811.277.450.950 – xylosidases MeSH D08.811.277.450.950.249 – endo-1,4-beta xylanases MeSH D08.811.277.450.950.500 – xylan endo-1,3-beta-xylosidase
Sources: en.wikipedia.org
Nuclear magnetic resonance spectroscopy of proteins (usually abbreviated protein NMR) is a field of structural biology in which NMR spectroscopy is used to obtain information about the structure and dynamics of proteins, and also nucleic acids, and their complexes. The field was pioneered by Richard R. Ernst and Kurt Wüthrich at the ETH, and by Ad Bax, Marius Clore, Angela Gronenborn at the NIH, and Gerhard Wagner at Harvard University, among others. Structure determination by NMR spectroscopy usually consists of several phases, each using a separate set of highly specialized techniques. The sample is prepared, measurements are made, interpretive approaches are applied, and a structure is calculated and validated. NMR involves the quantum-mechanical properties of the central core ("nucleus") of the atom. These properties depend on the local molecular environment, and their measurement provides a map of how the atoms are linked chemically, how close they are in space, and how rapidly they move with respect to each other. These properties are fundamentally the same as those used in the more familiar magnetic resonance imaging (MRI), but the molecular applications use a somewhat different approach, appropriate to the change of scale from millimeters (of interest to radiologists) to nanometers (bonded atoms are typically a fraction of a nanometer apart), a factor of a million. This change of scale requires much higher sensitivity of detection and stability for long term measurement.
True muscle weakness (or neuromuscular weakness) describes a condition where the force exerted by the muscles is less than would be expected, for example muscular dystrophy. Perceived muscle weakness (or non-neuromuscular weakness) describes a condition where a person feels more effort than normal is required to exert a given amount of force but actual muscle strength is normal, for example myalgic encephalomyelitis/chronic fatigue syndrome. In some conditions, such as myasthenia gravis, muscle strength is normal when resting, but true weakness occurs after the muscle has been subjected to exercise. This is also true for some cases of chronic fatigue syndrome, where objective post-exertion muscle weakness with delayed recovery time has been measured and is a feature of some of the published definitions.
García, Blanco & Rinderknecht (2026) provide estimates of body mass of Neoglyptatelus uruguayensis. Corro et al. (2026) revise the type materials of members of the genus Proeutatus from the Santa Cruz Formation (Argentina), and report that the type specimens of the species P. carinatus and P. deleo can be identified with certainty, unlike the type specimens of the species P. oenophorus, P. lagena and P. distans. The first specimen of Eutatus seguini preserved with the entirety of the caudal armor is described from the Pleistocene strata from the Laguna Melincué area (Santa Fe Province, Argentina) by Barasoain et al. (2026). Barasoain et al. (2026) describe fossil material of the big hairy armadillo from the Pleistocene strata of the La Paz Formation (Bolivia), representing the northernmost record of the species reported to date and the first known fossil evidence of presence of the species in high-altitude environments.
== Ecology == Exopolysaccharides can facilitate the attachment of nitrogen-fixing bacteria to plant roots and soil particles, which mediates a symbiotic relationship. This is important for colonization of roots and the rhizosphere, which is a key component of soil food webs and nutrient cycling in ecosystems. It also allows for successful invasion and infection of the host plant. Bacterial extracellular polymeric substances can aid in bioremediation of heavy metals as they have the capacity to adsorb metal cations, among other dissolved substances. This can be useful in the treatment of wastewater systems, as biofilms are able to bind to and remove metals such as copper, lead, nickel, and cadmium. The binding affinity and metal specificity of EPS varies, depending on polymer composition as well as factors such as concentration and pH. In a geomicrobiological context, EPS have been observed to affect precipitation of minerals, particularly carbonates. EPS may also bind to and trap particles in biofilm suspensions, which can restrict dispersion and element cycling. Sediment stability can be increased by EPS, as it influences cohesion, permeability, and erosion of the sediment. There is evidence that the adhesion and metal-binding ability of EPS affects mineral leaching rates in both environmental and industrial contexts. These interactions between EPS and the abiotic environment allow for EPS to have a large impact on biogeochemical cycling.
Sources: en.wikipedia.org
To completely block the uptake of iodine-131 by the purposeful addition of perchlorate ions to a populace's water supply, aiming at dosages of 0.5 mg/kg-day, or a water concentration of 17 ppm, would therefore be grossly inadequate at truly reducing radioiodine uptake. Perchlorate ion concentrations in a region's water supply would need to be much higher, at least 7.15 mg/kg of body weight per day, or a water concentration of 250 ppm, assuming people drink 2 liters of water per day, to be truly beneficial to the population at preventing bioaccumulation when exposed to a radioiodine environment, independent of the availability of iodate or iodide drugs. The continual distribution of perchlorate tablets or the addition of perchlorate to the water supply would need to continue for no less than 80–90 days, beginning immediately after the initial release of radioiodine was detected. After 80–90 days passed, released radioactive iodine-131 would have decayed to less than 0.1% of its initial quantity, at which time the danger from biouptake of iodine-131 is essentially over. In the event of a radioiodine release, the ingestion of prophylaxis potassium iodide, if available, or even iodate, would rightly take precedence over perchlorate administration, and would be the first line of defense in protecting the population from a radioiodine release.
In addition to CYP2B6, CYP2A6 may be involved in the metabolism of selegiline to a lesser extent. Birth control pills containing the synthetic estrogen ethinylestradiol and a progestin like gestodene or levonorgestrel have been found to increase peak levels and overall exposure to oral selegiline by 10- to 20-fold. High levels of selegiline can lead to loss of MAO-B selectivity and inhibition of MAO-A as well. This increases susceptibility to side effects and interactions of non-selective monoamine oxidase inhibitors (MAOIs), such as tyramine-induced hypertensive crisis and serotonin toxicity when combined with serotonergic medications. However, this study had a small sample size of four individuals as well as other methodological limitations. The precise mechanism underlying the interaction is unknown, but is likely related to cytochrome P450 inhibition and consequent inhibition of selegiline first-pass metabolism by ethinylestradiol. In contrast to birth control pills containing ethinylestradiol, menopausal hormone therapy with estradiol and levonorgestrel did not modify peak levels of selegiline and only modestly increased overall exposure (+59%). Hence, menopausal hormone therapy does not pose the same risk of interaction as ethinylestradiol-containing birth control pills when taken together with selegiline. Overall exposure to selegiline with oral selegiline has been found to be 23-fold lower in people taking anticonvulsants known to strongly activate drug-metabolizing enzymes. The anticonvulsants included phenobarbital, phenytoin, carbamazepine, and amobarbital.
=== December === 4 December – Recent studies reveal that the heart contains a small control center — an independent neural network that regulates its rhythm. Gaining deeper insight into this intricate and varied system, which proves to be far more sophisticated than earlier believed, may pave the way for innovative therapies for cardiovascular conditions.
=== Terminology === In 2021, a study in the UK showed that few are able to label the structure of the vulva correctly. There are many sexual slang terms used for the vulva. "Cunt", a medieval word for the vulva and once the standard term, has become a vulgarism, and in other uses one of the strongest offensive and abusive swear words in English-speaking cultures. The word has been replaced in normal usage by a few euphemisms including "pussy" (vulgar slang) and "fanny" (UK), which used to be a common pet name. In the UK, these terms have other non-sexual meanings that lend themselves to double entendres, such as "pussy", which is used as a term of endearment for a pet cat, "pussy cat". In North American informal use, the term "pussy" can also refer to a weak or effeminate man, and "fanny" is a term used for the buttocks. Other slang terms are "muff", "snatch", and "twat". "Vagina" is often incorrectly used as a synonym for vulva since it is separate from that anatomy.
The infantry regiments of the division rotated responsibility to conduct the Citizens' Military Training Camps each year at Camp McClellan. The division participated in Fourth Corps Area or Third Army command post exercises in conjunction with other Regular Army, National Guard and Organized Reserve units, but unlike Regular and Guard units, the 82nd Division did not participate as an organized unit in the Fourth Corps Area maneuvers and the Third Army maneuvers of 1938, 1940, and 1941 due to a lack of enlisted personnel and equipment, with the officers and a few enlisted reservists assigned to fill vacant slots in organized units to bring them to war strength for the exercises, with others assigned duties as umpires or support personnel.
Sources: en.wikipedia.org
Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.
Dry powder is kept frozen, desiccated, and shielded from light. Dissolved material is aliquoted and frozen to limit freeze-thaw cycles. Short-term refrigerated storage is common for working solutions.
Russia registers it as a prescription nasal product. Most other markets classify it as a research chemical with no approved medical use. Oversight of purity and labeling is consequently minimal in those markets.
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.